precigen, inc. discovers and develops the next generation of gene and cellular therapies in the united states. it also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. in addition, the company offers ultravector platform that incorporates advanced dna construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbil15, a gene that enhances functional characteristics of immune cells; sleeping beauty, a non-viral transposon/transposase system; attsite recombinases, which breaks and rejoins dna at specific sequences; adenoverse technology platform, a library of engineered adenovector serotypes; and l. lactis is a food-grade bacterium. additionally, it provides rheoswitch inducible gene switch that provides qua
Company profile
Ticker
PGEN
Exchange
Website
CEO
Helen Sabzevari
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
INTREXON CORP
SEC CIK
Corporate docs
Subsidiaries
Exemplar Genetics, LLC • Precigen ActoBio, Inc. • Precigen ActoBio Holdings, Inc. • ActoBio Laboratories Belgium BVBA • Intrexon ActoBiotics NV ...
PGEN stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
14 May 24
8-K
Precigen Reports First Quarter 2024 Financial Results and Business Updates
14 May 24
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Precigen Reports Full Year 2023 Financial Results and Business Updates
19 Mar 24
8-K
Departure of Directors or Certain Officers
8 Feb 24
EFFECT
Notice of effectiveness
18 Jan 24
CORRESP
Correspondence with SEC
12 Jan 24
8-K
Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference
8 Jan 24
UPLOAD
Letter from SEC
4 Jan 24
Transcripts
PGEN
Earnings call transcript
2023 Q4
19 Mar 24
PGEN
Earnings call transcript
2023 Q2
9 Aug 23
PGEN
Earnings call transcript
2023 Q2
9 Aug 23
PGEN
Earnings call transcript
2023 Q1
10 May 23
PGEN
Earnings call transcript
2022 Q3
10 Nov 22
PGEN
Earnings call transcript
2022 Q2
9 Aug 22
PGEN
Earnings call transcript
2021 Q2
10 Aug 21
PGEN
Earnings call transcript
2020 Q4
2 Mar 21
PGEN
Earnings call transcript
2020 Q4
1 Mar 21
PGEN
Earnings call transcript
2020 Q2
10 Aug 20
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.74 mm | 17.74 mm | 17.74 mm | 17.74 mm | 17.74 mm | 17.74 mm |
Cash burn (monthly) | (no burn) | 516.92 k | 7.92 mm | 8.11 mm | 4.70 mm | 5.22 mm |
Cash used (since last report) | n/a | 822.67 k | 12.61 mm | 12.91 mm | 7.47 mm | 8.31 mm |
Cash remaining | n/a | 16.92 mm | 5.13 mm | 4.83 mm | 10.27 mm | 9.44 mm |
Runway (months of cash) | n/a | 32.7 | 0.6 | 0.6 | 2.2 | 1.8 |
Institutional ownership, Q4 2023
18.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 75.14 mm |
Total shares | 45.82 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Kirk Randal J | 45.82 mm | $75.14 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 May 24 | Kirk Randal J | Common Stock | Other | Acquire J | Yes | No | 0 | 6,085,471 | 0.00 | 6,085,471 |
2 May 24 | Kirk Randal J | Common Stock | Other | Acquire J | Yes | No | 0 | 8,896,412 | 0.00 | 41,017,803 |
2 May 24 | Kirk Randal J | Common Stock | Other | Dispose J | Yes | No | 0 | 691,929 | 0.00 | 0 |
2 May 24 | Kirk Randal J | Common Stock | Other | Dispose J | Yes | No | 0 | 1,383,858 | 0.00 | 0 |
2 May 24 | Kirk Randal J | Common Stock | Other | Dispose J | Yes | No | 0 | 832,500 | 0.00 | 0 |
2 May 24 | Kirk Randal J | Common Stock | Other | Dispose J | Yes | No | 0 | 2,497,500 | 0.00 | 0 |
2 May 24 | Kirk Randal J | Common Stock | Other | Dispose J | Yes | No | 0 | 4,995,000 | 0.00 | 0 |
2 May 24 | Kirk Randal J | Common Stock | Other | Dispose J | Yes | No | 0 | 19,711 | 0.00 | 0 |
2 May 24 | Kirk Randal J | Common Stock | Other | Dispose J | Yes | No | 0 | 59,133 | 0.00 | 0 |
2 May 24 | Kirk Randal J | Common Stock | Other | Dispose J | Yes | No | 0 | 118,266 | 0.00 | 0 |
News
Cantor Fitzgerald Reiterates Overweight on Precigen
15 May 24
Stifel Maintains Buy on Precigen, Maintains $7 Price Target
15 May 24
HC Wainwright & Co. Reiterates Buy on Precigen, Maintains $6 Price Target
15 May 24
Precigen Q1 EPS $(0.10) Misses $(0.09) Estimate, Sales $1.06M Miss $1.48M Estimate
14 May 24
Precigen To Present Late-Breaking Abstract For Pivotal Phase 2 Study Data For PRGN-2012 AdenoVerse Immunotherapy For The Treatment Of Patients With Recurrent Respiratory Papillomatosis At The 2024 ASCO Annual Meeting
24 Apr 24
Press releases
Precigen Reports First Quarter 2024 Financial Results and Business Updates
14 May 24
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
24 Apr 24
Actym Therapeutics Appoints Thomas Smart as CEO
24 Apr 24
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
12 Mar 24
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
5 Mar 24